Tezepelumab attenuates exertional symptom burden in severe asthma: insights from a real-world cohort
{{output}}
Background: Exertional symptom burden is an important yet insufficiently characterised component of morbidity in severe asthma. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), reduces exacerbatio... ...
